About Dr. Sartor’s Research
Between 2010—2013, the U.S. Food and Drug Administration approved six new drugs for the treatment of advanced prostate cancer. Dr. Sartor played a lead role in the development of two of these drugs and served in an advisory role for two others. This is unprecedented progress, as these are the first new treatment options offering hope for men with advanced disease since 2004, and they were only possible through large, multi-institutional clinical research trials.
Because of the vital importance of novel treatment options like these, Dr. Sartor zealously focuses much of his time on better understanding advanced prostate cancer and the development of new drugs that make a difference for patients with this disease. Additionally, Dr. Sartor and his team of collaborators, including basic researchers and physician scientists at Tulane, LSU, and other institutions, are trying to better understand the genetics of prostate cancer in more detail. The project involves the collection of clinical data and complex genetic testing of tissue samples from men with various stages of prostate cancer in an effort to determine what type of genetic defects contribute to cancer risk, progression and drug responsiveness. This long-term research effort could yield important insights into prostate cancer not only for the subjects and their families, but for a variety of other cancer patients as well. Though it is an extremely difficult task, there is also an expanded effort to develop a new class of prostate cancer drugs starting with a basic laboratory approach. Donations to Dr. Sartor’s Prostate Cancer Research Fund are used to support these and other prostate cancer research initiatives being pursued by Dr. Sartor and his collaborative prostate cancer team. These efforts are designed to provide the very best of prostate cancer care to patients today, and even better care for patients tomorrow.